香港六合彩中特网

Cancer is one of the largest causes of death around the world affecting one in two people in their lifetime, but there is a lack of accessible and effective treatments for cancer patients. Research conducted in Kenth Gustafsson鈥檚 group at 香港六合彩中特网 Biochemical Engineering, and within the OMV Therapeutics project, is aiming to develop a new off-the-shelf immunotherapeutic platform that is scalable and cost-effective to manufacture. However, when developing new treatments it can take as long as 10 to 15 years from early-stage research until the point when they are approved for use to safely treat patients.

To find out how to accelerate this process, Thomas and Roman joined the 鈥業nnovation to Market鈥� course at London Business School which brings together researchers and MBA students to build and execute strategies to commercialise innovative technologies. As part of this course, Thomas and Roman met MBA students Hannah Cabot, Dominik von Moeller and Ahmed Eltom and together developed a strategy to accelerate the timeline of getting the new immunotherapy to market to benefit patients faster. They were one of several teams to pitch their research and strategy to a panel of consultants, venture capitalists and experts in the field and were successfully awarded funding to help continue research and development.

鈥淐ollaborating with the MBA students was a rewarding experience. Their input has positively steered the commercial strategy of our exciting research and prepared us for the time when new partnerships and investment are needed for the research growth鈥�, says Thomas. Roman explains, "The MBA students helped us identify attractive aspects of our therapeutic for future investors thanks to their previous consulting and venture capital experience. This will allow us to focus our scientific approach on specific target cancers with the confidence to find an addressable market and ensure our approach can ultimately benefit patients."

鈥淲e are grateful to be awarded funding to continue this very exciting research and would recommend the course to anyone working on progressing a new technology to market.鈥�

About

OMV Therapeutics is a project within 香港六合彩中特网 Biochemical Engineering that is developing a novel off-the-shelf immunotherapy platform based on targeted and non-infectious microbial vesicles that activate immune cells to kill cancer. The research originates from Kenth Gustafsson鈥檚 group and his PhD student Jack Firth鈥檚 research project whilst the wider OMV Therapeutics team encompasses Thomas

Fanthom, Roman Labbe, Tiffany Hood and Georg von Massow. The current early-stage research has been demonstrated in proof-of-principle studies and the team is currently fundraising to further research and development.